Observational studyThe Journal of dermatology2025

Real-world safety and effectiveness of adalimumab in patients with pyoderma gangrenosum: Interim analysis of a post-marketing observational study in Japan.

Toshiyuki Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.